LON:ABZA - ABZENA/PAR VTG FPD 0.002 Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseGBX 15.75
Today's RangeGBX 15.75 - GBX 15.75
52-Week RangeGBX 24.50 - GBX 53
Average Volume26,706 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. It provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging conjugation technology. In addition, it provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.

Receive ABZA News and Ratings via Email

Sign-up to receive the latest news and ratings for ABZA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

ABZENA/PAR VTG FPD 0.002 (LON:ABZA) Frequently Asked Questions

What is ABZENA/PAR VTG FPD 0.002's stock symbol?

ABZENA/PAR VTG FPD 0.002 trades on the London Stock Exchange (LON) under the ticker symbol "ABZA."

What price target have analysts set for ABZA?

3 brokerages have issued twelve-month target prices for ABZENA/PAR VTG FPD 0.002's stock. Their predictions range from GBX 40 to GBX 62. On average, they anticipate ABZENA/PAR VTG FPD 0.002's stock price to reach GBX 47.33 in the next twelve months. View Analyst Price Targets for ABZENA/PAR VTG FPD 0.002.

What is the consensus analysts' recommendation for ABZENA/PAR VTG FPD 0.002?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABZENA/PAR VTG FPD 0.002 in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABZENA/PAR VTG FPD 0.002.

Has ABZENA/PAR VTG FPD 0.002 been receiving favorable news coverage?

Press coverage about ABZA stock has been trending very positive on Wednesday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ABZENA/PAR VTG FPD 0.002 earned a news impact score of 3.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of ABZENA/PAR VTG FPD 0.002's key competitors?

Who are ABZENA/PAR VTG FPD 0.002's key executives?

ABZENA/PAR VTG FPD 0.002's management team includes the folowing people:
  • Dr. William John Edward Burt, CEO & Exec. Director (Age 50)
  • Prof. Sunil Shaunak, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Antony Godwin Ph.D., Co-Founder
  • Prof. Steve Brocchini Ph.D., Co-Founder
  • Dr. Jim Mills, Sr. VP of Technical Operations

How do I buy shares of ABZENA/PAR VTG FPD 0.002?

Shares of ABZA and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ABZENA/PAR VTG FPD 0.002's official website?

The official website for ABZENA/PAR VTG FPD 0.002 is http://www.abzena.com/.

How can I contact ABZENA/PAR VTG FPD 0.002?

ABZENA/PAR VTG FPD 0.002's mailing address is Babraham Hall, Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom. The company can be reached via phone at +44-1223-903498.

MarketBeat Community Rating for ABZENA/PAR VTG FPD 0.002 (LON ABZA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about ABZENA/PAR VTG FPD 0.002 and other stocks. Vote "Outperform" if you believe ABZA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABZA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: What is a stock split?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel